Antibiotic susceptibility and T type identification of Streptococcus pyogenes isolated from pediatric outpatients with pharyngotonsillitis
スポンサーリンク
概要
- 論文の詳細を見る
Between April 2002 and March 2004, 533 <I>Streptococcus pyogenes</I> isolates were collected from pediatric outpatients with pharyngotonsillitis. The susceptibility of 14 antibiotics (8 β-lacatams, 4 macrolides, clindamycin, and telithromycin) were determined against these isolates. The MIC<SUB>90s</SUB> of β-lactams were as follows: cefditoren=cefdinir=cefcapene (0.008μg/mL), cefpodoxime (0.016μg/mL), ampicillin=amoxicillin=faropenem (0.031μg/mL), and cefaclor (0.125μg/mL). The MIC90 of telithromycin was 0.031μg/mL. Erythromycin, clarithromycin, and azithromycin of macrolides were less active than β-lacatams. We also determined the presence or absence of macrolide-resistance genes of <I>ermB, mefA</I>, and <I>ermTR</I> for all isolates by PCR. Of 533 isolates, 17 strains (3.2%) had the <I>ermB</I> gene, 26 strains (4.9%) the <I>mefA</I> gene, and 3 strains (0.5%) the <I>ermTR</I> gene. Strains having the <I>ermB</I> gene showed high resistance to all macrolides tested, and strains having the <I>mef</I>A gene were resistant to these agents with MIC<SUB>90S</SUB> of ≥ 1μg/mL, except for josamycin and clindamycin. The susceptibility to macrolides of strains having the <I>ermTR</I> gene was similar to that of strains having the <I>mefA</I> gene. Predominant T types were T12 (32.3%), followed by T4 (18.8%), T1 (10.1%), T13 (8.3%), and T25 (7.5%). Macrolide-resistance strains were distributed in T types, but among strains having the <I>mefA</I> gene, more than half were T25 showing an increase. These results suggest that continuous surveillance for <I>Streptococcus pyogenes</I> is required.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.